According to a 2024 study covering thousands of subjects, semaglutide does not appear to be associated with an increased risk of adverse psychiatric conditionsinsomnia included
Trends in endocrinology and metabolism: TEM
A recent large-scale clinical trial has confirmed that tirzepatide, a dual GIP and GLP-1RAs, resulted in a weight loss of up to 20.9% in adults with body fat mass of 30 or more after 72-week follow-up [22]
Florida Surgery and Weight Loss Center currently helps eligible patients access medical weight loss options such as tirzepatide and semaglutide when clinically appropriate
The potential of GLP-1R agonists as multi-faceted therapeutic agents extends their benefits to various pain conditions, including inflammatory, neuropathic, visceral pain, and headaches (Table 3)
Medications like Ozempic contain ingredients that mimic natural GLP-1 hormones